Servicesource International Inc (SREV), Recro Pharma Inc (REPH): Altai Capital And Broadfin Capital’s Latest Moves

According to a recent filing with the Securities and Exchange Commission, Altai Capital, run by Rishi Bajaj, Toby Symonds and Steve Tesoriere, has increased its holding of Servicesource International Inc (NASDAQ:SREV). As a result, Altai Capital now holds 11.7 million shares, up from the 8.22 million shares reported in its latest 13F filing.

Phil Frohlich is also bullish on Servicesource International Inc (NASDAQ:SREV), having increased his fund’s investment in the company by 185% during the second quarter of this year. Prescott Group Capital Management reportedly holds 3.01 million shares valued at approximately $17.4 million. George McCabe, the manager of Portolan Capital Management, also sees Servicesource International Inc (NASDAQ:SREV) as a good investment and has built a new position for his fund during the same period of time. His fund currently holds 1.07 million shares worth $6.25 million. Chuck Royce, on the other hand, has chosen to limit his fund’s exposure to the stock and has reduced his stake by 20%. Royce & Associates has reported ownership of approximately 943,900 shares valued at $5.47 million in its latest 13F filing.

Kevin Kotler thinks Recro Pharma Inc (NASDAQ:REPH) stock is poised to go higher and has boosted his fund’s stake in the company. According to a recent filing with the Securities and Exchange commission, Kotler has added 500,000 shares to his fund’s previous position, taking it to 1.17 million shares. As a result, Broadfin Capital now has control over 15.2% of the company’s common stock.

From the hedge funds we track, Broadfin Capital is the only one invested in Recro Pharma Inc (NASDAQ:REPH). The company engages in the development of non-opioid therapeutics for the treatment of pain. On September 4th, Recro Pharma Inc (NASDAQ:REPH) announced an update to its research strategy for Dex-IN (intranasal dexmedetomidine). Based on prior observations, a revised approach to the study is “the best path forward”, according to Gerri Henwood, Recro Pharma’s President and Chief Executive Officer.

Free Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.